Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;9(11):810.
doi: 10.3390/photonics9110810. Epub 2022 Oct 28.

Artificial Intelligence to Aid Glaucoma Diagnosis and Monitoring: State of the Art and New Directions

Roberto Nunez  1 , Alon Harris  2 , Omar Ibrahim  3 , James Keller  1 , Christopher K Wikle  4 , Erin Robinson  5 , Ryan Zukerman  6 , Brent Siesky  2 , Alice Verticchio  2 , Lucas Rowe  7 , Giovanna Guidoboni  1   8
Affiliations

Artificial Intelligence to Aid Glaucoma Diagnosis and Monitoring: State of the Art and New Directions

Roberto Nunez et al. Photonics. 2022 Nov.

Abstract

Recent developments in the use of artificial intelligence in the diagnosis and monitoring of glaucoma are discussed. To set the context and fix terminology, a brief historic overview of artificial intelligence is provided, along with some fundamentals of statistical modeling. Next, recent applications of artificial intelligence techniques in glaucoma diagnosis and the monitoring of glaucoma progression are reviewed, including the classification of visual field images and the detection of glaucomatous change in retinal nerve fiber layer thickness. Current challenges in the direct application of artificial intelligence to further our understating of this disease are also outlined. The article also discusses how the combined use of mathematical modeling and artificial intelligence may help to address these challenges, along with stronger communication between data scientists and clinicians.

Keywords: artificial intelligence; glaucoma; glaucoma diagnosis; glaucoma progression; mathematical modeling; statistical modeling.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Alon Harris would like to disclose that he received remuneration from AdOM, Qlaris, Luseed, and Cipla for serving as a consultant, and he serves on the board of AdOM, Qlaris, and Phileas Pharma. Alon Harris holds an ownership interest in AdOM, Luseed, Oxymap, Qlaris, Phileas Pharma, SlitLed, and QuLent. Giovanna Guidoboni would like to disclose that she received remuneration from Foresite Healthcare and Qlaris for serving as a consultant.

Figures

Figure 1.
Figure 1.
Comparison of Heidelberg retinal tomography (HRT)- vs. optical coherence tomography (OCT)-derived parameters: (left) cup area, (center) cup to disk area ratio, (right) mean retinal nerve fiber layer (RNFL) thickness.
Figure 2.
Figure 2.
Schematic representation of the data set enhancement process.
Figure 3.
Figure 3.
In both graphs, each dot represents a patient in the IGPS, plotted with respect to IOP and mean arterial pressure (MAP). On the right, patients are colored according to the label assigned to them by the fuzzy C-means algorithm applied to the enhanced dataset. The physiology-informed machine learning approach was able to quantify relative contributions of IOP and blood pressure to OAG risk for patients in these clusters.
See this image and copyright information in PMC

References

    1. Harris A; Guidoboni G; Siesky B; Mathew S; Vercellin AC; Rowe L; Arciero J Ocular blood flow as a clinical observation: Value, limitations and data analysis. Prog. Retin. Eye Res 2020, 78, 100841. - PMC - PubMed
    1. GBD 2019. Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: An analysis for the Global Burden of Disease Study. Lancet Glob. Health 2021, 9, e144–e160. - PMC - PubMed
    1. Leske CM; Heijl A; Hussein M; Bengtsson B; Hyman L; Komaroff E Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: The early manifest glaucoma trial. Arch. Ophthalmol 2003, 121, 48–56. - PubMed
    1. Weinreb RN; Harris A (Eds.) Ocular Blood Flow in Glaucoma; Kugler Publications: Amsterdam, The Netherlands, 2009; Volume 6.
    1. McCarthy J; Minsky M; Rochester N; Shannon C A Proposal for the Dartmouth Summer Research Project on Artificial Intelligence, archived from the original on 2007-08-26, retrieved 2006-04-09 retrieved 10:47 (UTC), 9th of April 2006. AI Mag. 2006, 27, 12.

LinkOut - more resources